InvestSMART

Radiopharm Theranostics Limited (ASX:RAD)

ALERT: Price-sensitive ASX Announcement for RAD
Current share price for RAD : $0.010 -0.01 (-50%)+
Announcement
Release
8 Apr 2026 9:00AM
Price at Release
$0.020
Full Release
download
Summary
Radiopharm Theranostics has advanced to the third cohort in its Phase 1 'HEAT' clinical trial for the radiotherapeutic asset 177Lu-RAD202, targeting HER2-positive advanced solid tumors. The company received a positive recommendation from the Data Safety and Monitoring Committee to increase the dose to 130mCi, highlighting the trial's favorable safety profile. This progression marks a critical step in the dose escalation process, which is expected to be completed by the end of 2026. Radiopharm Theranostics, listed on both ASX and NASDAQ, focuses on developing innovative radiopharmaceuticals for oncology, with a pipeline including five Phase 1 trials and one Phase 2 trial.
Key Points
  • Radiopharm Theranostics advances to Cohort 3 in Phase 1 HEAT trial
  • Positive recommendation received from Data Safety and Monitoring Committee
  • Next dose level set at 130mCi for 177Lu-RAD202
  • Trial focuses on HER2-positive advanced solid tumors
  • Phase 1 dose escalation expected to complete by end of 2026
  • Radiopharm specializes in radiotherapeutics for oncology
  • Listed on ASX and NASDAQ
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.